For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
As the global economy mends, the 2021 growth of Piracetam will have significant change from previous year. According to our (LP Information) latest study, the global Piracetam market size is USD million in 2022 from USD million in 2021, with a change of % between 2021 and 2022. The global Piracetam market size will reach USD million in 2028, growing at a CAGR of % over the analysis period.
The United States Piracetam market is expected at value of US$ million in 2021 and grow at approximately % CAGR during review period. China constitutes a % market for the global Piracetam market, reaching US$ million by the year 2028. As for the Europe Piracetam landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 5-year period.
Global main Piracetam players cover Jiangsu Chenpai Pharmaceutical Group, Shandong Weigao Pharmaceutical, Shandong Xinhua Pharmaceutical, and Guorui Pharmaceutical Group, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
This report presents a comprehensive overview, market shares, and growth opportunities of Piracetam market by product type, application, key players and key regions and countries.
Segmentation by type: breakdown data from 2017 to 2022 in Section 2.3; and forecast to 2028 in section 10.7.
- Injection
- Capsule
- Tablets
Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 10.8.
- Cerebrovascular Disease
- Traumatic Brain Injuries
- Toxic Encephalopathy
- Other
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
- Americas
- - United States
- - Canada
- - Mexico
- - Brazil
- APAC
- - China
- - Japan
- - Korea
- - Southeast Asia
- - India
- - Australia
- Europe
- - Germany
- - France
- - UK
- - Italy
- - Russia
- Middle East & Africa
- - Egypt
- - South Africa
- - Israel
- - Turkey
- - GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major players in the market. The key players covered in this report: Breakdown data in in Chapter 3.
- Jiangsu Chenpai Pharmaceutical Group
- Shandong Weigao Pharmaceutical
- Shandong Xinhua Pharmaceutical
- Guorui Pharmaceutical Group
- Shanghai Modern Hazen Shangqiu Pharmaceutical
- Duoduo Pharmaceutical
- Shandong Fangming Pharmaceutical Group
- Hangzhou Minsheng Pharmaceutical
- Shandong Qidu Pharmaceutical
- Guangdong Litai Pharmaceutical
- Chenxin Pharmaceutical
- Ruiyang Pharmaceutical
- Hainan Huanglong Pharmaceutical
- Hainan Tongyong Kangli Pharmaceutical
- China Resources Shuanghelimin Pharmaceutical Jinan
- Tianjin Jinyao group Henan Lixin Pharmaceutical
- Zhejiang Ruixin Pharmaceutical
- Furen Pharmaceutical Group
- Jiangsu Yabangshengyuan Pharmaceutical
- Shandong Xinyi Pharmaceutical
- Shanghai Shangyao Xinyi Pharmaceutical
- Shanghai Huayuan Anhui Renji Pharmaceutical
- Shanghai Pukang Pharmaceutical
- Northeast Pharmaceutical Group Renhetang Pharmaceutical
- Huazhong Pharmaceutical
- Nanjing baijingyu Pharmaceutical
- Hefei Jiulian Pharmaceutical
- Yichang Renfu Pharmaceutical
- Guangdong Sancai Shiqi District Pharmaceutical
- Guangdong South Ch
- Guangdong Bangmin Pharmaceutical
- Kaifeng Pharmaceutical Group
- Jiangsu Shenhua Pharmaceutical
- Jiangsu Pengyao Pharmaceutical
- Hunan Dinuo Pharmaceutical
- Shijiazhuang No. 4 Pharmaceutical
- Chengdu Tongde Pharmaceutical
- Shanxi Bailu Pharmaceutical
- Jiangxi Qingchun Kangyuan Pharmaceutical
- Liaoning Tianlong Pharmaceutical
- Liaoyuan Yulong Yadong Pharmaceutical
- Changchun Changqing Pharmaceutical Group